RobertEdwardRatnerMD

Diabetes, Lipid Metabolism

Professor, Medicine, Georgetown University School of Medicine

Dr. Ratner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
110 Irving St NW
Ste 2A38
Washington, DC 20010
Phone+1 202-877-2848

Fax+1 202-877-6292

Dr. Robert Ratner is an endocrinologist in Washington, DC on faculty in the Division of endocrinology and metabolism at Georgetown University. He is chief medical officer at Virta Health. He received his medical degree from Baylor College of Medicine and has been in practice 40 years. He Served as chief scientific and medical officer for the American Diabetes Association from 2012-2016.

Beth Israel Deaconess Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1980 - 1982
Baylor College of MedicineResidency, Internal Medicine, 1977 - 1980
Baylor College of MedicineClass of 1977

PubMed

85 citations
The safety and tolerability of GLP‐1 receptor agonists in the treatment of type 2 diabetes: a review
Vanita R. Aroda, Robert E. Ratner
Diabetes/metabolism Research and Reviews. 2011-09-01
457 citations
Diabetic kidney disease: a report from an ADA Consensus Conference.
Katherine R. Tuttle, George L. Bakris, Rudolf W. Bilous, Jane L. Chiang, Ian H. de Boer
Diabetes Care. 2014-10-01
591 citations
Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association.
Richard A. Insel, Jessica L. Dunne, Mark A. Atkinson, Jane L. Chiang, Dana Dabelea
Diabetes Care. 2015-10-01

Lectures

Clinical Diabetes and Endocrinology in 2013
National Jewish Health, Snowmass, Colorado - 1/19/2013
Practical Ways to Achieve Targets in Diabetes Care
University of Colorado Denver, Keystone, Colorado - 7/12/2012

Diabetes Reversal Leader Virta Health Demonstrates Promising Results on Mitigating COVID-19 Severity for People with Type 2 DiabetesJune 28th, 2021
No Mention of Diabetes, Virus-Deaths LinkSeptember 23rd, 2020
Tech Entrepreneurs' Newest Ally: The FDAApril 24th, 2020
Join now to see all

Diabetes Prevention Program Outcomes Study - Phase 2National Institute Of Diabetes And Digestive And Kidney Diseases2009–2012
The Metformin-Exenatide-Insulin (MEXELIN) TrialNational Center For Research Resources2008–2009
Long Term DPP Follow-Up StudyNational Institute Of Diabetes And Digestive And Kidney Diseases2003–2008
Stop Atherosclerosis In Native Diabetics Study (SANDS)National Heart, Lung, And Blood Institute2006–2007
Inhaled Insulin Using The Aerx IDMS VS SC Insulin VIA SyNational Center For Research Resources2005
Diabetes Prevention ProgramNational Institute Of Diabetes And Digestive And Kidney Diseases1996–2002
Diabetes Prevention Program (Ddd-2)National Institute Of Diabetes And Digestive And Kidney Diseases1998
Primary Prevention TrialNational Institute Of Diabetes And Digestive And Kidney Diseases1994–1995